Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.63 |
| ▸ | RET | P07949 | 4/20 | 0.63 |
| ▸ | FLT3 | P36888 | 4/20 | 0.63 |
| ▸ | SRC | P12931 | 3/20 | 0.63 |
| ▸ | CSF1R | P07333 | 3/20 | 0.63 |
| ▸ | FLT1 | P17948 | 3/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | JAK3 | P52333 | 3/20 | 0.63 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | FLT4 | P35916 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | AURKA | O14965 | 2/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188872 | 1.00 | KDR (0.63) | KDRPDGFRBFGFR1RETFLT3 | |
| SCHEMBL4457557 | 0.83 | KDR (0.56) | KDRPDGFRBFGFR1RETFLT3 | |
| SCHEMBL4457553 | 0.83 | KDR (0.56) | KDRPDGFRBFGFR1RETFLT3 | |
| SCHEMBL5200796 | 0.80 | KDR (0.74) | KDRPDGFRBFGFR1RETFLT3 | |
| SCHEMBL5200799 | 0.80 | KDR (0.74) | KDRPDGFRBFGFR1RETFLT3 | |
| SCHEMBL6000971 | 0.77 | TLK2 (0.62) | KDRPDGFRBFGFR1RETFLT3 | |
| SCHEMBL2768013 | 0.77 | KDR (0.59) | KDRPDGFRBFGFR1RETFLT3 | |
| Semaxanib SCHEMBL19572 | 0.77 | RET (1.00) | KDRPDGFRBFGFR1RETFLT3 | |
| Semaxanib SCHEMBL29373311 | 0.77 | RET (1.00) | KDRPDGFRBFGFR1RETFLT3 | |
| SCHEMBL6000975 | 0.77 | TLK2 (0.62) | KDRPDGFRBFGFR1RETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303084-B2 | Human C-FMS antibodies | AMGEN INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140105916-A1 | HUMAN C-FMS ANTIGEN BINDING PROTEINS | AMGEN INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140079706-A1 | COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8513199-B2 | Methods for treating conditions associated with c-fms | AMGEN INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110311546-A1 | Angiopoietin-2 specific binding agents | AMGEN, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20090093539-A1 | ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | WONG KIN-PING | 2009-04-09 | — | — | US | disclosed |
| EP-1773817-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006012374-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-6906093-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040266688-A1 | Methods for modulating endometrium | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-30 | — | — | US | disclosed |
| US-20030176487-A1 | 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | SUGEN, INC. | 2003-09-18 | — | — | US | disclosed |
| US-6469032-B2 | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION; ANTICARCINOGENIC, -DIABETIC, -PROLIFERATIVE AND -INFLAMMATORY AGENTS; VASCULAR SYSTEM DISORDERS | SUGEN, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020102608-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2002-08-01 | — | — | US | disclosed |
| US-20010027207-A1 | 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | TANG PENG CHO (US) | 2001-10-04 | — | — | US | disclosed |
| US-6225335-B1 | MODULATES TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION; FOR THERAPY OF CANCER, ATHEROSCLEROSIS, ARTHRITIS AND RESTENOSIS AND METABOLIC DISEASES SUCH AS DIABETES | SUGEN, INC. | 2001-05-01 | — | — | US | disclosed |
| EP-0934931-A2 | 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators | Sugen, Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5886020-A | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0769947-A4 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 1998-09-30 | — | — | EP | disclosed |
| EP-0769947-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | Sugen, Inc. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996040116-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027207-A1 | 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | ERBB2, MKI67, ABL1 | KDR 460/4885PDGFRB 325/4885FGFR1 200/4885 |
| US-20030176487-A1 | 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | ERBB2, MKI67, ABL1 | KDR 460/4885PDGFRB 325/4885FGFR1 200/4885 |
| US-20020102608-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | PTPRJ, ERBB2, JAK2 | KDR 204/4885PDGFRB 285/4885FGFR1 330/4885 |
| US-20090093539-A1 | ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | PGF, VEGFA, TEK | KDR 10/4885PDGFRB 78/4885FGFR1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.